5 Best Revenue Growth Stocks to Buy

2. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Number of Hedge Fund Investors In Q1 2023: 29

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the handful of biotechnology companies that are developing treatments for genetic disorders and diseases. It has been growing its revenue since 2017, but the growth has slowed down since then with the latest figure for 2022 sitting at 3.39%. The five year average revenue growth rate is 168%.

After scouring through 943 hedge funds for their investments during 2023’s March quarter, Insider Monkey discovered that 29 had bought and owned Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s shares. David Witzke and Michael Gregory’s Avidity Partners Management is the largest investor in our database due to its investment of $85 million.

Follow Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)